MEK-ERK Feedback: Why Blocking the MAPK Pathway Is Not Simple

The Feedback Wiring

Active ERK phosphorylates multiple upstream components to reduce pathway flux: it inhibits RAF directly, phosphorylates the adaptor SOS to weaken RAS activation, and induces the DUSP phosphatases and Sprouty proteins that further blunt signalling.

In a normal cell this keeps ERK output within a narrow band. In a tumour with an activating mutation, the feedback is already engaged, holding the pathway at a high but self-limited level.

What Happens When You Add an Inhibitor

A MEK or ERK inhibitor lowers ERK activity, which releases the negative feedback. Upstream, RAS and RAF become more active, receptor signalling increases, and the pathway pushes back toward its previous output.

The result is partial and often transient suppression, with pathway activity rebounding over hours to days unless the feedback loop is also addressed.

Why Combinations Help

Combining a BRAF inhibitor with a MEK inhibitor suppresses the pathway at two points and delays feedback-driven rebound, which is why BRAF plus MEK inhibition outperforms BRAF inhibition alone in BRAF V600-mutant melanoma.

Adding an EGFR antibody in BRAF V600-mutant colorectal cancer counters feedback reactivation of EGFR, which is prominent in that tissue and blunts BRAF inhibition given alone.

Feedback and Non-V600 Mutations

Class 3 BRAF mutants, which are kinase-impaired, actually depend on upstream RAS activity and on RTK signalling, so relieving feedback can worsen their signalling. This is one reason drug strategies differ between BRAF mutation classes.

Vertical inhibition, hitting the pathway at several levels at once, is the general principle that has emerged from this biology.

Interpretation Notes

Feedback biology is why a MAPK-pathway alteration on a report does not translate simply into single-drug sensitivity; the tissue context and mutation class shape the response.

Newer agents, including RAF-dimer inhibitors and ERK inhibitors, are designed partly to be less vulnerable to feedback reactivation.

Key Takeaways

• ·ERK feeds back to inhibit RAF, SOS and RAS activation and to induce DUSP and Sprouty.
• ·MEK or ERK inhibitors relieve this feedback, causing upstream reactivation and rebound.
• ·BRAF plus MEK, and BRAF plus EGFR in colorectal cancer, counter feedback and work better.
• ·Feedback effects differ by BRAF mutation class, shaping drug choice.